Bristol-Myers Squibb Company (BMY): A Bull Case Theory
We came across a bullish thesis on Bristol-Myers Squibb Company on CompoundingLab’s Substack. In this article, we will summarize the bulls’ thesis on BMY.
Bristol Myers Squibb Co (BMY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Pzena Investment Management Richard S. Pzena | 14,901,604 | $672,062,341 | +1% | 2.17% |
| 2. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 14,833,977 | $669,012,363 | +32% | 0.42% |
| 3. | AQR Capital Management Cliff Asness | 9,463,981 | $426,352,329 | +56% | 0.27% |
| 4. | GLG Partners Noam Gottesman | 9,228,160 | $416,190,017 | +24% | 0.72% |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 4,721,300 | $212,930,630 | +323% | 0.43% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $47.58 | 4,250 | $202,215.00 | 83,513 | 2025-04-25 | Filing | |
| $55.05 | 2,000 | $110,096.00 | 104,626 | 2025-02-20 | Filing | |
| $54.84 | 1,823 | $99,999.97 | 63,932 | 2025-02-14 | Filing | |
| $54.68 | 1,830 | $100,055.25 | 62,109 | 2024-11-01 | Filing | |
| $49.78 | 2,000 | $99,560.00 | 82,672 | 2023-12-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $47.33 | 56,000 | $2,650,480.00 | 167,379 | 2025-09-02 | Filing | |
| $44.23 | 378 | $16,718.94 | 5,066 | 2025-08-02 | Filing | |
| $38.01 | 97 | $3,701.83 | 0 | 2025-05-09 | Filing | |
| $55.62 | 700 | $38,930.50 | 11,760 | 2024-11-04 | Filing | |
| $61.25 | 17,986 | $1,101,642.50 | 27,868 | 2023-08-24 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 195,984,009 | $8,838,878,806 | 0.13% | |
| 2. | 175,515,165 | $7,915,733,960 | 0.14% | |
| 3. | 96,595,232 | $4,356,444,963 | 0.15% | |
| 4. | 86,180,664 | $3,886,749,848 | 0.23% | |
| 5. | 73,040,323 | $3,294,118,567 | 0.53% |
News See All
Bristol Myers Squibb Company (BMY) Slipped due to Lowered EPS Guidance
Cullen Capital Management, LLC, operating under the name Schafer Cullen Capital Management, Inc. (SCCM), has released its “SCCM Value Equity Strategy” third-quarter investor letter.
Scotiabank Initiates Coverage on Bristol Myers (BMY) with Sector Perform Rating and $45 Target
In the third quarter of 2025, Bristol-Myers Squibb Company (NYSE:BMY) reported revenue of $12.22 billion, a 2.77% increase from the same period last year.
15 Best Passive Income Stocks to Buy Right Now
The idea of generating passive income has been gaining a lot of attention recently.
Bernstein Assigns Bristol-Myers Squibb Company (BMY) a Hold Rating
Bristol-Myers Squibb Company (NYSE:BMY) is one of the best undervalued stocks to buy under $50.
Jim Cramer Offered Insights on These 16 Stocks
“So it was the government shutdown and some insane comments from OpenAI about a government backstop because of gigantic spending that caused the sell-off.
14 Best Undervalued Stocks to Buy Under $50
He stated that since the beginning of the year, the market has been very bifurcated, not just in terms of performance but also in terms of earnings and profit margins.
BofA Remains Neutral on Bristol-Myers Squibb Company (BMY), Expects Low Single-Digit Growth in the Long Term
On November 3, 2025, BofA raised its price target on Bristol-Myers Squibb Company (NYSE:BMY) from $50 to $52, reiterating its “Neutral” rating.
12 Deep Value Stocks to Invest In
Market concerns on valuation, particularly in the tech space, and a potential for correction seem to be taking center stage in investor discussions.
Jim Cramer’s Recent Thoughts on These 8 Stocks
“This morning, when the market was down, my colleagues at Squawk on the Street, David Faber and Carl Quintanilla, were questioning me about whether we just turn to the same old same old growth stocks...
Hedge Fund Resource Center Billionaire Hedge Funds
